| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/30/2002 | WO2002041881A2 Repinotan kit |
| 05/30/2002 | WO2002041880A2 Use of pyrazolo[4,3-d]pyrimidines |
| 05/30/2002 | WO2002041872A1 Generation of therapeutic microfoam |
| 05/30/2002 | WO2002041834A2 Atorvastatin hemi-calcium form vii |
| 05/30/2002 | WO2002041827A2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 05/30/2002 | WO2002022599A3 Chemokine receptor binding heterocyclic compounds |
| 05/30/2002 | WO2002020736A9 Proteases |
| 05/30/2002 | WO2002018581A9 G-protein coupled receptors |
| 05/30/2002 | WO2002015919A3 Saratin for inhibiting platelet adhesion to collagen |
| 05/30/2002 | WO2002013805A3 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 05/30/2002 | WO2002002756A3 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 05/30/2002 | WO2002000611A3 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 05/30/2002 | WO2001098270A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 05/30/2002 | WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 05/30/2002 | WO2001092333A3 Use of adnf for enhancing learning and memory |
| 05/30/2002 | WO2001087330A3 Compositions and methods for achieving immune suppression |
| 05/30/2002 | WO2001085686A3 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 05/30/2002 | WO2001077055A3 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 05/30/2002 | WO2001072714A3 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2001064646A3 Hydrazones and analogs as cholesterol lowering agents |
| 05/30/2002 | WO2001048187A3 A molecular switch for regulating mammalian gene expression |
| 05/30/2002 | WO2001043759A3 Use of 11cby popypeptides and polynuceotides |
| 05/30/2002 | WO2001016300A3 Method of identifying inhibitors of cdc25 |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | US20020065419 Cyclobutenedione compounds |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065393 Human hypoxanthine- (guanine) phosphoribosy1 transferase-2 |
| 05/30/2002 | US20020065391 Compound for use in the treatment of arthritis, inflammatory bowel disease, nervous system and cardiovascular disorders, arteriosclerosis, restenoses, diabetes, grafted organ damage, asthma, allergies, tumor metastasis and malaria |
| 05/30/2002 | US20020065327 Pharmaceutically active compounds and methods of use thereof |
| 05/30/2002 | US20020065315 For therapy and prophylaxis of asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, etc. |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065299 Administering for therapy of mitochondria medited disease |
| 05/30/2002 | US20020065298 Mitochondria protecting agents for treating mitochondria associated diseases |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065289 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065278 Non-imidazole aryloxyalkylamines |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065269 3-Sulfonylamino-c5 to c8-methyleneimino-2-carboxylic acid compound is effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases |
| 05/30/2002 | US20020065264 Heterocylic leaving group containing -o-Het, or -s-Het, wherein Heterocyclic rings selected from pyridine, pyrole, furan, pyrimidine or proline derivatives |
| 05/30/2002 | US20020065231 Method for producing biologically active products |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064843 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/30/2002 | US20020064830 Nucleotide sequences for use as diagnostic tools |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064553 Large liposome composition not increasing ldl levels and method of treating atherosclerosis related thereto |
| 05/30/2002 | US20020064516 Pharmaceutical compositions comprising TGF-beta |
| 05/30/2002 | CA2432804A1 Porous polymeric biomaterials, preparation method and uses |
| 05/30/2002 | CA2430100A1 Antiangiogenic agents |
| 05/30/2002 | CA2430037A1 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 05/30/2002 | CA2429817A1 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 05/30/2002 | CA2429699A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/30/2002 | CA2429649A1 Drugs and foods improving the quality of life and process for producing the same |
| 05/30/2002 | CA2429647A1 Use of thienopyrimidines |
| 05/30/2002 | CA2429645A1 Use of pyrazolo[4,3-d]pyrimidines |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429605A1 Indol derivative and their use as inhibitors of p38 kinase |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429570A1 Pyrimidine derivatives |
| 05/30/2002 | CA2429480A1 Ophthalmological preparations |
| 05/30/2002 | CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | CA2429328A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases |
| 05/30/2002 | CA2429326A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors |
| 05/30/2002 | CA2429313A1 Novel sulfonamide-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2429310A1 Repinotan kit |
| 05/30/2002 | CA2429309A1 Novel carbamate-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2429260A1 Medicinal compositions comprising cs-866 and a diuretic |
| 05/30/2002 | CA2428191A1 Acid derivatives useful as serine protease inhibitors |
| 05/30/2002 | CA2427444A1 3-arylindole derivatives and their use as cb2 receptor agonists |
| 05/30/2002 | CA2427334A1 Methods and compositions for the treatment of diseases of the eye |
| 05/30/2002 | CA2427184A1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | CA2398924A1 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof |
| 05/30/2002 | CA2363951A1 Modulating ramp activity |
| 05/30/2002 | CA2363935A1 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 05/29/2002 | EP1209152A1 Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alpha v beta 3 antagonism |
| 05/29/2002 | EP1208855A1 Novel embolizing compositions |
| 05/29/2002 | EP1208842A2 Regulation of the immune system |
| 05/29/2002 | EP1208384A2 Methods and compositions for modulating oxidized ldl transport |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208198A2 Egfh2 genes and gene products |
| 05/29/2002 | EP1208110A1 Antisense modulation of focal adhesion kinase expression |
| 05/29/2002 | EP1208104A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 05/29/2002 | EP1208103A2 Reverse-turn mimetics and methods relating thereto |
| 05/29/2002 | EP1208100A1 Selective antagonists of a2b adenosine receptors |
| 05/29/2002 | EP1208099A1 4,5-diaryloxazole compounds with prostaglandin i2 (pgi2) agonistic activity |
| 05/29/2002 | EP1208097A2 Substituted oxoazaheterocyclyl compounds |
| 05/29/2002 | EP1208096A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 05/29/2002 | EP1208092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor |
| 05/29/2002 | EP1208088A2 Fluorene derivatives as integrin inhibitors |
| 05/29/2002 | EP1207900A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 05/29/2002 | EP1207884A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 05/29/2002 | EP1207881A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 05/29/2002 | EP1207877A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 05/29/2002 | EP1207868A1 Pharmaceutical tramadol salts |
| 05/29/2002 | EP1207867A1 Oral pharmaceutical forms of administration with a delayed action |
| 05/29/2002 | EP1207866A1 Delayed-action form of administration containing tramadol saccharinate |
| 05/29/2002 | EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy |